Compare · BSX vs TCMD
BSX vs TCMD
Side-by-side comparison of Boston Scientific Corporation (BSX) and Tactile Systems Technology Inc. (TCMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BSX and TCMD operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BSX is the larger of the two at $72.16B, about 126.0x TCMD ($572.9M).
- Over the past year, BSX is down 51.3% and TCMD is up 148.6% - TCMD leads by 199.9 points.
- BSX has been more active in the news (12 items in the past 4 weeks vs 2 for TCMD).
- BSX has more recent analyst coverage (25 ratings vs 9 for TCMD).
- Company
- Boston Scientific Corporation
- Tactile Systems Technology Inc.
- Price
- $48.71+0.31%
- $25.46+0.28%
- Market cap
- $72.16B
- $572.9M
- 1M return
- -13.89%
- -2.17%
- 1Y return
- -51.30%
- +148.63%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 2016
- News (4w)
- 12
- 2
- Recent ratings
- 25
- 9
Boston Scientific Corporation
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, and micro and drainage catheters to treat cancer. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.
Tactile Systems Technology Inc.
Tactile Systems Technology, Inc., a medical technology company, engages in the development and provision of medical devices for chronic diseases in the United States. The company offers Flexitouch Plus system, a pneumatic compression device for the treatment of lymphedema; and Entre system, a portable pneumatic compression device that is used for the at-home treatment of venous disorders, such as lymphedema and chronic venous insufficiency, including venous leg ulcers. The company was incorporated in 1995 and is headquartered in Minneapolis, Minnesota.
Latest BSX
- Chairman, President & CEO Mahoney Michael F gifted 386,755 shares (SEC Form 4)
- Boston Scientific downgraded by Wolfe Research
- Boston Scientific downgraded by Wells Fargo with a new price target
- Director Ludwig Edward J bought $202,914 worth of shares (3,580 units at $56.68), increasing direct ownership by 16% to 25,359 units (SEC Form 4)
- Director Pegus Cheryl bought $99,987 worth of shares (1,770 units at $56.49) (SEC Form 4)
- Director Habiger David C bought $251,098 worth of shares (4,450 units at $56.43), increasing direct ownership by 47% to 13,878 units (SEC Form 4)
- SEC Form SD filed by Boston Scientific Corporation
- FRACTURE IDE trial of the Boston Scientific SEISMIQ™ 4CE Coronary Intravascular Lithotripsy Catheter meets primary safety and effectiveness endpoints
- Boston Scientific Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Boston Scientific Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
Latest TCMD
- Tactile Medical Launches Next-Generation AffloVest® Airway Clearance Therapy
- Tactile Medical to Present at the William Blair 46th Annual Growth Stock Conference
- CHIEF FINANCIAL OFFICER Birkemeyer Elaine M. sold $113,404 worth of shares (4,631 units at $24.49), decreasing direct ownership by 3% to 130,188 units (SEC Form 4)
- SEC Form 144 filed by Tactile Systems Technology Inc.
- Director Asbury Valerie L. was granted 6,521 shares, increasing direct ownership by 13% to 55,343 units (SEC Form 4)
- Director Huggenberger Raymond was granted 6,521 shares, increasing direct ownership by 12% to 62,841 units (SEC Form 4)
- Director King Laura G. was granted 6,521 shares, increasing direct ownership by 34% to 25,569 units (SEC Form 4)
- Director Pearson Andrea was granted 6,521 shares, increasing direct ownership by 765% to 7,373 units (SEC Form 4)
- Director Shafer David Brent was granted 6,521 shares, increasing direct ownership by 13% to 55,343 units (SEC Form 4)
- Director Volkart Carmen B was granted 6,521 shares, increasing direct ownership by 17% to 44,219 units (SEC Form 4)